The stock of Heron Therapeutics Inc (HRTX) has gone up by 13.60% for the week, with a 3.27% rise in the past month and a 27.35% rise in the past quarter. The volatility ratio for the week is 8.22%, and the volatility levels for the past 30 days are 7.73% for HRTX. The simple moving average for the last 20 days is 6.19% for HRTX’s stock, with a simple moving average of 56.28% for the last 200 days.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
Company’s 36-month beta value is 1.70.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRTX is 142.96M, and currently, short sellers hold a 17.79% ratio of that floaft. The average trading volume of HRTX on May 07, 2024 was 2.23M shares.
HRTX) stock’s latest price update
Heron Therapeutics Inc (NASDAQ: HRTX)’s stock price has soared by 8.81 in relation to previous closing price of 2.61. Nevertheless, the company has seen a gain of 13.60% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-12 that Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with CapitalOne repeating the rating for HRTX by listing it as a “Overweight.” The predicted price for HRTX in the upcoming period, according to CapitalOne is $6 based on the research report published on April 23, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $5, previously predicting the price at $4. The rating they have provided for HRTX stocks is “Buy” according to the report published on March 13th, 2024.
Guggenheim gave a rating of “Buy” to HRTX, setting the target price at $24 in the report published on May 27th of the previous year.
HRTX Trading at 4.87% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.80% of loss for the given period.
Volatility was left at 7.73%, however, over the last 30 days, the volatility rate increased by 8.22%, as shares surge +3.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.23% upper at present.
During the last 5 trading sessions, HRTX rose by +13.60%, which changed the moving average for the period of 200-days by +105.80% in comparison to the 20-day moving average, which settled at $2.68. In addition, Heron Therapeutics Inc saw 67.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRTX starting from Forbes William P, who purchase 25,000 shares at the price of $1.09 back on Nov 17 ’23. After this action, Forbes William P now owns 79,000 shares of Heron Therapeutics Inc, valued at $27,250 using the latest closing price.
Collard Craig A, the Chief Executive Officer of Heron Therapeutics Inc, purchase 150,000 shares at $0.92 during a trade that took place back on Nov 16 ’23, which means that Collard Craig A is holding 186,496 shares at $137,970 based on the most recent closing price.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.49 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.87. The total capital return value is set at -0.77. Equity return is now at value -2408.88, with -46.70 for asset returns.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.33. The debt to equity ratio resting at -5.2. The interest coverage ratio of the stock is -36.88.
Currently, EBITDA for the company is -107.72 million with net debt to EBITDA at -1.4. When we switch over and look at the enterprise to sales, we see a ratio of 4.56. The receivables turnover for the company is 2.11for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.37.
Conclusion
In a nutshell, Heron Therapeutics Inc (HRTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
